公开(公告)号：US20240361328A1

公开(公告)日：2024-10-31

申请号：US18646665

申请日：2024-04-25

申请人： JUN HUANG

发明人： JUN HUANG ,  YIFEI HU

IPC分类号： G01N33/58 ,  C07K1/13 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0783 ,  G01N33/569

CPC分类号： G01N33/58 ,  C07K1/13 ,  C07K16/2803 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0636 ,  G01N33/56972 ,  G01N33/582 ,  C07K2317/92 ,  C07K2319/22 ,  C07K2319/33 ,  C07K2319/60

摘要： The present invention discloses a versatile application of a multimer technology for detecting, manufacturing, and profiling chimeric antigen receptor (CAR)-expressing cells. These antigen-multimers exhibit remarkable specificity, sensitivity, and precision in identifying CAR cells. Moreover, they facilitate over 100-fold magnetic enrichment of rare CAR-T cells, enhancing their detectability. Beyond CAR detection, the multimer technology selectively stimulates CAR-expressing cells, both in soluble and surface-bound formats, during CAR-T cell manufacturing. Unlike existing technologies (such as anti-CD28/CD3 magnetic beads) that non-specifically stimulate and expand all T cells, the multimer approach ensures that only CAR-expressing cells are targeted. Consequently, this yields a CAR-T cell product with significantly higher purity, enhancing treatment efficacy. Furthermore, the multimer technology offers flexibility in CAR detection through nucleotide labeling. This enables high-dimensional CAR-T cell profiling via single-cell multi-omics analyses. Antigen multimers can be seamlessly adapted to other CAR systems by switching the antigen ligand.

公开(公告)号：US20240360472A1

公开(公告)日：2024-10-31

申请号：US18294799

申请日：2022-08-03

申请人： STRAND THERAPEUTICS INC.

发明人： Jaspreet S. KHURANA ,  Aalok SHAH ,  Tasuku KITADA

IPC分类号： C12N15/86 ,  A61K38/00 ,  C07K14/005 ,  C07K14/54

CPC分类号： C12N15/86 ,  C07K14/005 ,  C07K14/5434 ,  A61K38/00 ,  C12N2760/16122 ,  C12N2770/36143

摘要： The present disclosure relates to a polynucleotide or a set of polynucleotides comprising a first nucleic acid molecule encoding an innate immune inhibitor, e.g., an influenza non-structural (NS1) protein, and a second nucleic acid molecule encoding a heterologous target mRNA. The disclosure also includes methods of making the polynucleotides, methods of modifying a cell, and methods of treating a subject using the same.

公开(公告)号：US20240360468A1

公开(公告)日：2024-10-31

申请号：US18291282

申请日：2022-07-26

申请人： BASF Agricultural Solutions Seed US LLC

发明人： Kavita Bitra ,  Alberto Bressan

IPC分类号： C12N15/82 ,  C07K14/005

CPC分类号： C12N15/8286 ,  C07K14/005 ,  C12N2720/00022 ,  C12N2760/20022 ,  C12N2770/00022 ,  C12N2770/40022

摘要： Herein, is describe a new technology that exploits modified-virus-like particles (VLP) to improve deliverability and increase effectiveness of dsRNAs/chemicals/peptides to difficult-to-control phytophagous insect pests, including hemipteran and lepidopteran insects. This technology has also the potential to control plant pathogens including fungi, like Asian Soybean Rust (ASR).

公开(公告)号：US20240360243A1

公开(公告)日：2024-10-31

申请号：US18630602

申请日：2024-04-09

申请人： Elevation Oncology, Inc.

发明人： Birgit M. SCHOEBERL ,  Ulrik B. NIELSEN ,  Michael J. FELDHAUS ,  Arumugam MURUGANANDAM ,  David BUCKLER

IPC分类号： C07K16/32 ,  A61K9/00 ,  A61K31/337 ,  A61K31/517 ,  A61K33/243 ,  A61K39/00 ,  A61K39/395 ,  C07K16/28

CPC分类号： C07K16/32 ,  A61K9/0019 ,  A61K31/337 ,  A61K31/517 ,  A61K39/3955 ,  A61K39/39558 ,  C07K16/2863 ,  A61K33/243 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.

公开(公告)号：US20240360238A1

公开(公告)日：2024-10-31

申请号：US18626765

申请日：2024-04-04

申请人： CRISPR THERAPEUTICS AG

发明人： Bradley R. Pearse ,  Michael Cooke ,  Anthony Boitano ,  Rahul Palchaudhuri ,  Sean McDonough ,  Rajiv Panwar ,  Jacob Glanville

IPC分类号： C07K16/28 ,  A61K35/12 ,  A61K35/545 ,  A61K38/00 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  A61P37/06 ,  C07K7/64

CPC分类号： C07K16/2896 ,  A61K35/545 ,  A61K47/6817 ,  A61K47/6831 ,  A61K47/6849 ,  A61P35/00 ,  A61P37/06 ,  C07K7/64 ,  C07K16/2803 ,  A61K2035/124 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

摘要： The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

公开(公告)号：US20240360237A1

公开(公告)日：2024-10-31

申请号：US18765476

申请日：2024-07-08

申请人： GlaxoSmithKline Intellectual Property Management Limited

发明人： Robert B. HENDERSON

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P37/02

CPC分类号： C07K16/2887 ,  A61P37/02 ,  C07K16/2875 ,  A61K2039/507 ,  C07K2317/76

摘要： The present invention relates to a CD20 binding antibody which is capable of depleting B cells, and a BLyS binding antibody which is capable of antagonizing BLyS, as a combination for use in the treatment of an autoimmune disorder. The invention also relates to dosages, duration of treatment and time lapses between administration of the CD20 binding antibody which is capable of depleting B cells, and the BLyS binding antibody which is capable of antagonizing BLyS.

公开(公告)号：US20240360234A1

公开(公告)日：2024-10-31

申请号：US18657550

申请日：2024-05-07

申请人： Nkarta, Inc.

发明人： James Barnaby Trager ,  Alexandra Leida Liana Lazetic ,  Ivan Chan ,  Chao Guo ,  Katherine Jamboretz

IPC分类号： C07K16/28 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C12N15/90

CPC分类号： C07K16/2875 ,  C07K14/7051 ,  C07K14/70578 ,  C07K14/7155 ,  C12N15/907 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2310/20 ,  C12N2800/80

摘要： Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy. Several embodiments relate to genetic modifications to the immune cells, such as Natural Killer (NK) cells, to reduce, substantially, reduce, or eliminate expression of a marker by the immune cells that would otherwise cause them to be self-targeted by the CAR. In several embodiments, the CAR targets CD70, and in some embodiments is used for renal cell carcinoma immunotherapy.

公开(公告)号：US20240360232A1

公开(公告)日：2024-10-31

申请号：US18612039

申请日：2024-03-21

申请人： SANOFI BIOTECHNOLOGY ,  REGENERON PHARMACEUTICALS, INC.

发明人： Raolat Abdulai ,  Elizabeth Laws ,  Leda Mannent ,  Lacey Robinson ,  Marcella Ruddy

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K45/06 ,  A61P11/00

CPC分类号： C07K16/2866 ,  A61K45/06 ,  A61P11/00 ,  A61K2039/505 ,  A61K2039/545

摘要： Methods for treating or preventing chronic obstructive pulmonary disease (COPD) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

公开(公告)号：US20240360230A1

公开(公告)日：2024-10-31

申请号：US18432780

申请日：2024-02-05

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Daniel B. Dix ,  Xiaolin Tang

IPC分类号： C07K16/28 ,  A61K9/00 ,  A61K39/395 ,  A61K47/18 ,  A61M5/315

CPC分类号： C07K16/2866 ,  A61K9/0019 ,  A61K39/39591 ,  A61K47/183 ,  A61M5/315 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/94

摘要： The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

公开(公告)号：US20240360222A1

公开(公告)日：2024-10-31

申请号：US18662493

申请日：2024-05-13

申请人： OSAKA UNIVERSITY

发明人： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC分类号： C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09

CPC分类号： C07K16/2839 ,  A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33

摘要： Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.